Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function.
about
The TWEAK receptor Fn14 is a potential cell surface portal for targeted delivery of glioblastoma therapeuticsIRS1 is highly expressed in localized breast tumors and regulates the sensitivity of breast cancer cells to chemotherapy, while IRS2 is highly expressed in invasive breast tumorsA Bioinformatics Resource for TWEAK-Fn14 Signaling PathwayProapoptotic and antiinvasive activity of Rac1 small molecule inhibitors on malignant glioma cellsPredictive gene signature of response to the anti-TweakR mAb PDL192 in patient-derived breast cancer xenograftsTWEAK-independent Fn14 self-association and NF-κB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domainMinimizing the non-specific binding of nanoparticles to the brain enables active targeting of Fn14-positive glioblastoma cells.Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells.Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.High β-catenin/Tcf-4 activity confers glioma progression via direct regulation of AKT2 gene expression.Identification of aurintricarboxylic acid as a selective inhibitor of the TWEAK-Fn14 signaling pathway in glioblastoma cellsDevelopment and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.The Src homology 3 domain-containing guanine nucleotide exchange factor is overexpressed in high-grade gliomas and promotes tumor necrosis factor-like weak inducer of apoptosis-fibroblast growth factor-inducible 14-induced cell migration and invasioTROY (TNFRSF19) promotes glioblastoma survival signaling and therapeutic resistance.Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) promotes glioblastoma cell chemotaxis via Lyn activation.TWEAK activation of the non-canonical NF-κB signaling pathway differentially regulates melanoma and prostate cancer cell invasion.Mcl-1 mediates TWEAK/Fn14-induced non-small cell lung cancer survival and therapeutic response.The TWEAK-Fn14 system as a potential drug target.Implications of Rho GTPase Signaling in Glioma Cell Invasion and Tumor Progression.Role of Akt in human malignant glioma: from oncogenesis to tumor aggressiveness.Prognostic significance of TWEAK expression in colorectal cancer and effect of its inhibition on invasion.SGEF Is Regulated via TWEAK/Fn14/NF-κB Signaling and Promotes Survival by Modulation of the DNA Repair Response to TemozolomideElevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.The small GTPase RhoG mediates glioblastoma cell invasion.TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.The possible functions of duplicated ets (GGAA) motifs located near transcription start sites of various human genesConstruction of a recombinant lentivirus containing human microRNA-7-3 and its inhibitory effects on glioma proliferation.A Novel Signaling Complex between TROY and EGFR Mediates Glioblastoma Cell Invasion.Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.FN14 expression correlates with MET in NSCLC and promotes MET-driven cell invasion.EGFRvIII-Stat5 Signaling Enhances Glioblastoma Cell Migration and Survival.PDZ-RhoGEF Is a Signaling Effector for TROY-Induced Glioblastoma Cell Invasion and Survival
P2860
Q26795601-1ADCAC99-E9B1-4C09-B1CF-690F2120271BQ28288521-9680422E-B05E-459E-81CE-81588C48DD5DQ28729829-7CC61BF2-00A0-42EC-90C9-576544CD91C1Q34446327-F97D2D7A-2FD4-435B-8970-7095EE62CB2BQ34465302-03E1A30A-ABB2-4955-B376-ED6C429459B3Q34764239-C732794C-5BB6-47E7-AE94-728B4F008EDCQ34785621-D9FEA75B-1DE7-4A14-BD60-3D29CD8BB872Q34964906-D6706321-F480-4BE4-899A-33FBF656DF5AQ35018711-B3E76928-70CF-4F6B-9235-2905AB1515B3Q35021344-2E86E940-ED37-4031-928B-7597827737F9Q36254216-59FC8178-4B8B-4E6D-BC57-A6169409F5F0Q36469716-87E70358-AC97-4FF0-B9D6-F75A4A44AC2FQ37048438-E075F5D7-26A4-411E-8575-A44E7A2A9229Q37107309-018A67D0-03A9-43E6-8349-BD2F4A93331EQ37412022-5C7E7F2A-2081-491C-8D19-C667159A2D10Q37697186-1C2575EE-C61C-414C-8670-9EA3CDD25BA5Q37707092-BF46B8B9-9F16-4AE7-85AD-70E9BD6D6182Q38129961-296B6F8A-AB13-4A41-8157-E9E77C46B81FQ38151113-E4A50639-A912-4883-A931-89823A28DEAAQ38183283-596DFC69-C855-4FDB-BE1B-4F01DD41C434Q38334216-C3E14899-9D88-48FA-9D82-1E8084B8209CQ38803824-6A0EC9FD-4928-432C-90E6-AD99FF666797Q41865343-16F3D088-6CCC-4DEE-B814-FAC0B4288439Q41952641-4CF037A9-2BFA-46E0-81BD-CF52E4800100Q42004462-20004859-5BA1-49B1-8838-F2244E92867BQ42738749-CFCB4B53-B7B8-4CC1-98FC-903153E15BDCQ43087444-63A141BE-5DC5-413B-8653-BB1DDE8E907EQ47979201-E0C2FF9B-B424-47DE-BF43-02EA2A59EA51Q49908827-5249A6C6-5F93-47EE-B881-FC682CDFD0B1Q53058993-D0C55223-8037-4956-8EB5-EBF2FF37D823Q55457200-7B88E240-A4E1-4A7A-A953-47E29406B280Q58743409-D3C62E20-B96A-4054-A930-F2CB4B957140
P2860
Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor necrosis factor-like wea ...... is dependent on Akt2 function.
@en
Tumor necrosis factor-like wea ...... is dependent on Akt2 function.
@nl
type
label
Tumor necrosis factor-like wea ...... is dependent on Akt2 function.
@en
Tumor necrosis factor-like wea ...... is dependent on Akt2 function.
@nl
prefLabel
Tumor necrosis factor-like wea ...... is dependent on Akt2 function.
@en
Tumor necrosis factor-like wea ...... is dependent on Akt2 function.
@nl
P2093
P2860
P1476
Tumor necrosis factor-like wea ...... is dependent on Akt2 function.
@en
P2093
Benjamin A Savitch
Christopher Kingsley
David Carpentieri
Galen Hostetter
Jeffrey A Winkles
Joseph C Loftus
Matthew J Ennis
Nhan L Tran
Shannon P Fortin
Wendy S McDonough
P2860
P304
P356
10.1158/1541-7786.MCR-09-0194
P577
2009-10-27T00:00:00Z